Drug facts
Compounded tirzepatide vs Mounjaro
Quick answer
Same molecule, different standing. Mounjaro is tirzepatide approved to improve blood sugar in type 2 diabetes — in adults and, on its current label, in children 10 and older — and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. A compounded vial carries none of those approvals, no label of its own and no trial of its own.
What Mounjaro is approved for1
Section 1 of the current label, in full:
MOUNJARO® is indicated:
- as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
- to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events.
Weight management is not on that list. It belongs to the other tirzepatide product, Zepbound — the two are the same molecule approved for different conditions, set out in Mounjaro vs Zepbound.
What is the same1
The active molecule, and so the mechanism: tirzepatide acts on both the GIP and GLP-1 receptors — see how tirzepatide works. The boxed warning about thyroid C-cell tumors attaches to the molecule, and so do the contraindications that follow from it. And the dose range is Mounjaro’s own: 2.5 mg to a maximum of 15 mg once weekly in adults (10 mg in children), in 2.5 mg steps no sooner than four weeks apart — the same ladder as on the dosage chart.
What a compounded vial does not carry3
On the label — Mounjaro / Zepbound
Approval for diabetes. Mounjaro was reviewed and approved for glycemic control, with a stated population — including, now, children from age 10.
In a compounded vial
Not approved for any condition. FDA’s own wording: compounded drugs are not FDA-approved, and FDA does not verify their safety, effectiveness or quality before they are marketed.
On the label — Mounjaro / Zepbound
Evidence on blood sugar. In SURPASS-2, glycated hemoglobin fell by 2.01, 2.24 and 2.30 percentage points on tirzepatide 5, 10 and 15 mg over 40 weeks.
In a compounded vial
No trial has measured a compounded preparation’s effect on blood sugar — or on anything else. The figures people cite are the approved product’s.
On the label — Mounjaro / Zepbound
A fixed strength. Every pen and vial delivers the dose printed on it.
In a compounded vial
A concentration the pharmacy chose, so a milligram dose is a different mark on the syringe from a different vial — see units and milligrams.
If you have type 2 diabetes
This is where the difference stops being abstract. Tirzepatide lowers blood glucose, and both of its labels warn about hypoglycemia when it is combined with insulin or with a medicine that makes the body release insulin, such as a sulfonylurea — covered in interactions with other medicines. A diabetes regimen built around tirzepatide is usually adjusted around it, and that adjustment is the prescriber’s job whichever product is in the syringe.
If you are buying through a weight-loss program, its intake form is not a diabetes consultation. If blood sugar is the reason you are on tirzepatide, the person managing your diabetes should know exactly what you are taking, from whom, and at what concentration.
Switching from Mounjaro
The molecule does not change, so 5 mg of tirzepatide is 5 mg of tirzepatide on paper. What changes is how you measure it: a Mounjaro pen or single-dose vial holds a fixed dose; a compounded vial needs the dose converted to a volume at that vial’s concentration. Most dosing mistakes happen at exactly this step, which is why switching sellers, or switching molecules and the dose-in-units calculator exist. What the approved product now costs direct, set against the compounded market, is on is compounded tirzepatide still cheaper than Zepbound?
Questions
- Is compounded tirzepatide the same as Mounjaro?
- It contains the same active molecule, but it is not the same product. Mounjaro is FDA-approved for type 2 diabetes and for cardiovascular risk reduction in type 2 diabetes; a compounded preparation is not approved for any condition, has no label of its own and has not been tested in a trial.
- Is Mounjaro approved for weight loss?
- No. Mounjaro is approved to improve blood sugar in type 2 diabetes, in adults and children 10 and older, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk. The tirzepatide product approved for weight management is Zepbound.
- Is Mounjaro stronger than compounded tirzepatide?
- Milligram for milligram it is the same molecule, so neither is stronger by definition. The difference is that a Mounjaro dose is fixed and FDA-reviewed, while a compounded vial's strength is set by the pharmacy that made it and has not been reviewed.
- Can I switch from Mounjaro to compounded tirzepatide?
- Only with your prescriber. The milligram dose carries over on paper, but a compounded vial has to be measured by volume at its own concentration, and if you have type 2 diabetes the rest of your regimen may need to be adjusted around it.